Upadacitinib is a pharmaceutical raw material that functions as a Janus kinase (JAK) inhibitor. It is employed in the manufacturing of medications that modulate inflammatory processes associated with certain autoimmune and inflammatory conditions.
İçerik kapsamı: Bu sayfadaki bilgiler kimyasal tanımlama ile endüstriyel tedarik, araştırma ve üretim bağlamlarına ilişkindir. Tedavi iddiası, tıbbi tavsiye veya ilaç kullanım talimatı niteliği taşımaz.
Bu bileşiği tedarik ediyor veya sağlıyor musunuz?
Envanterinizi listeleyin veya satın alma talebi gönderin
CAS 1831899-72-9
Upadacitinib hemihydrate
active pharmaceutical ingredient
Upadacitinib
Janus kinase inhibitor
5-chloro-6-(1-(2-iminopyrrolidinyl) methyl)uracil hydrochloride
active pharmaceutical ingredient
Clindamycin
semi-synthetic lincosamide antibiotic
Erlotinib hydrochloride
active pharmaceutical ingredient
Erlotinib
active pharmaceutical ingredient
8-((3R,4S)-4-ethylpyrrolidin-3-yl)-3h-imidazo[1,2-a]pyrrolo[2,3-e]pyrazine dihydrocloride
pharmaceutical intermediate
8-((3R,4S)-4-ethylpyrrolidin-3-yl)-3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazine
Research compound for medicinal chemistry
(3S,4R)-3-ethyl-4-(1,5,7,10-tetrazatricyclo[7.3.0.02,6]dodeca-2(6),3,7,9,11-pentaen-12-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide
WYQFJHHDOKWSHR-MNOVXSKESA-N
CC[C@@H]1CN(C[C@@H]1C2=CN=C3N2C4=C(NC=C4)N=C3)C(=O)NCC(F)(F)F